The Reality
Medicare laboratory cuts were delayed until January 1, 2027.
That sounds like relief.
It isn’t.
Between May 1 and July 31, 2026, certain laboratories must report private payer data to CMS. That data will determine your Medicare reimbursement rates starting in 2027.
If that data is incomplete, mis-mapped, or distorted by billing errors, CMS will calculate lower median rates.
Those rates remain in effect for years.
At laboratory volumes, even a small reporting distortion compounds quickly.
This is not a billing task.
It is a revenue protection decision.
Where Labs Are Most Exposed
We consistently see risk in five areas:
• LCD/NCD validation gaps
• Modifier errors on high-volume tests
• Zero-dollar claims included incorrectly
• Incomplete reconciliation of private payer payments
• Denial patterns that distort true reimbursement data
Generic RCM platforms do not understand laboratory billing logic at this level.
And CMS does not adjust for your internal errors.
They calculate from what you submit.
What the Revenue Readiness Review Covers
The Laboratory Revenue Readiness Review is a structured assessment designed specifically for clinical laboratories.
We evaluate:
✔ 2025 finalized paid claim validation
✔ LCD/NCD logic at the line level
✔ Modifier usage accuracy
✔ Denial trend distortion
✔ Reporting workflow readiness
✔ Exposure to multi-year reimbursement compression
This is not a generic show and tell conversation.
It is a focused review of your revenue exposure before the reporting window closes.
Why Laboratories Choose ADS
Advanced Data Systems has been serving healthcare providers since 1977.
We have:
• Nearly 99% first-pass clean claim performance
• Processed nearly 50 million EDI transactions annually
• Built laboratory-specific billing rules into our system
• Embedded LCD/NCD compliance logic directly into our claims engine
• Never changed ownership
• Never discontinued a product
Laboratory billing is structurally different from general medical billing.
Your billing platform should reflect that.
"With MedicsRCM and their team, we’re operating more profitably and efficiently than we ever thought possible."
Minerva Ortiz-Rosario, Administrator
Tamarac Pathology Group, Homosassa FL